Page last updated: 2024-10-28
lidocaine and Foot and Mouth Disease
lidocaine has been researched along with Foot and Mouth Disease in 1 studies
Lidocaine: A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.
lidocaine : The monocarboxylic acid amide resulting from the formal condensation of N,N-diethylglycine with 2,6-dimethylaniline.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|
| " When infected mice were treated with different amounts of lidocaine (a local anesthetic, chemically defined as a tertiary amide compound), reduction in intensity of the pancreatic necrosis and in the number of PMN were observed." | 7.69 | Protective effect of lidocaine in the experimental foot-and-mouth disease pancreatitis. ( González, PH; Portiansky, EL, 1995) |
| " When infected mice were treated with different amounts of lidocaine (a local anesthetic, chemically defined as a tertiary amide compound), reduction in intensity of the pancreatic necrosis and in the number of PMN were observed." | 3.69 | Protective effect of lidocaine in the experimental foot-and-mouth disease pancreatitis. ( González, PH; Portiansky, EL, 1995) |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|
| Portiansky, EL | 1 |
| González, PH | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| A Single Center, Randomized, Double-Blind Controlled Study of Topical Endoluminal Pancreatic Duct Lidocaine for Prevention of Post-ERCP Pancreatitis[NCT00953199] | | 506 participants (Actual) | Interventional | 2010-03-31 | Completed |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Post ERCP Pancreatitis is the Primary Outcome.
The primary outcome of interest will be development of acute pancreatitis defined as new or worsening abdominal pain post-ERCP associated with an increase in serum amylase at least 3 times the upper limit of normal. (NCT00953199)
Timeframe: 24-48 hours post-procedure
| Intervention | participants (Number) |
|---|
| Lidocaine | 26 |
| Normal Saline | 20 |
Serum Amylase Levels
serum amylase levels are measure by a blood draw (NCT00953199)
Timeframe: measurement is taken 2 hrs after ERCP
| Intervention | units/liter (Mean) |
|---|
| Lidocaine | 130 |
| Normal Saline | 128 |
Other Studies
1 other study available for lidocaine and Foot and Mouth Disease